| 陶盛能,王小华,赵 敏.利妥昔单抗联合化疗对惰性B细胞淋巴瘤的疗效分析[J].肿瘤学杂志,2018,24(12):1191-1195. |
| 利妥昔单抗联合化疗对惰性B细胞淋巴瘤的疗效分析 |
| Efficacy of Rituximab Combined with Chemotherapy for Patients with Indolent Non-Hodgkin’s B-cell Lymphom |
| 投稿时间：2017-08-22 |
| DOI：10.11735/j.issn.1671-170X.2018.12.B010 |
|
 |
| 中文关键词: 利妥昔单抗 药物疗法 惰性B细胞淋巴瘤 疗效 |
| 英文关键词:rituximab chemotherapy indolent B-cell non-Hodgkin’s lymphoma efficacy |
| 基金项目: |
|
| 摘要点击次数: 1205 |
| 全文下载次数: 333 |
| 中文摘要: |
| 摘 要：［目的］ 分析利妥昔单抗联合化疗对惰性B细胞淋巴瘤(indolent B-cell non-Hodgkin’s lymphoma，iNHL)的疗效。［方法］ 收集2010年4月至2014年7月接受治疗的经病理确诊的82例iNHL患者，随机分为两组，对照组42例，观察组40例。两组均给予常规化疗，观察组在对照组基础上给予利妥昔单抗。［结果］ 治疗前后，两组CD3+、CD4+和CD4+/ CD8+水平均无明显差异(P>0.05)；治疗后，两组CD19+、乳酸脱氢酶(lactate dehydrogenase，LDH)均明显降低(P<0.05)，且与对照组相比，观察组CD19+、LDH降低更明显(P<0.05)。对照组有效率为64.2%，观察组为85.0%，观察组有效率较对照组高(P<0.05)。观察组1～3年无进展生存和总生存均较对照组明显高(P<0.05)。两组不良反应发生率差异无统计学意义 (P>0.05)。［结论］利妥昔单抗辅助化疗能有效控制 iNHL，对机体T淋巴细胞亚群的影响不明显，可有效抑制CD19+和LDH，无明显毒副作用。 |
| 英文摘要: |
| Abstract：［Objective］To evaluate the efficacy of rituximab combined with chemotherapy in treatment of patients with indolent non-Hodgkin’s B-cell lymphoma(iNHL). ［Methods］ Eighty two patients with iNHL admitted from April 2010 to July 2014 were randomly divided into control group(42 cases) and study group(40 cases). Both groups received routine chemotherapy，and additional rituximab therapy was given to patients in study group. ［Results］ There were no significant differences in CD3+，CD4+ and CD4+/ CD8+ levels in two groups before and after treatment. Compared with before treatment，the CD19+ and lactate dehydrogenase(LDH) levels were decreased in both groups(P<0.05). Compared with the control group，the CD19+ and LDH in the study group were decreased more significantly(P<0.05). The progress-free survival and overall survival within 3 years in the study group were significantly higher than those in the control group(P<0.05). There were significant differences in adverse effect rate between the two groups(P>0.05). ［Conclusion］ Rituximab combined with chemotherapy is more effective in treatment of iNHL without serious side effects，with the decrease of CD19+ and LDH，and little effect on T lymphocyte subsets. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |